Purpose: To investigate acute changes in glucose metabolism in liver and kidneys in vivo after a bolus injection of either fructose or glucose, using hyperpolarized [2-13 C]dihydroxyacetone. Methods: Spatially registered, dynamic, multislice MR spectroscopy was acquired for the metabolic products of [2-
INTRODUCTION
Gluconeogenesis (GNG) in the liver and to a lesser extent the kidney is integrally associated with whole body glucose homeostasis (1, 2) . This process is poorly controlled in diabetes, and it is now recognized that GNG is dysregulated in nonalcoholic fatty liver disease (NAFLD) (3) , which has prevalence of 80-90% in obese adults (4) . NAFLD can progress to nonalcoholic steatohepatitis (NASH), which is projected to be the primary cause for liver transplantation within the next decade (5) . GNG is likewise known to be disrupted in cirrhosis (3) , which results from progressive fibrotic liver injury. Invasive liver biopsy, despite its associated complications with bleeding and mortality, remains the primary method of monitoring the progression of NAFLD to NASH (6) or staging liver fibrosis (7) . The development of improved methodology for noninvasive diagnosis and monitoring of these conditions represents an extremely important unmet clinical need in hepatology.
The highly prevalent fructose-rich diet promotes liver injury. High-fructose diets have been shown to increase insulin resistance, hypertension, lipid synthesis, obesity, and metabolic syndrome (8) . It is believed that fructose toxicity is primarily related to its unregulated uptake and subsequent hepatic ATP depletion (9). The strong association of diet composition with NAFLD as well as progression to NASH indicates that derangement of energy metabolism underlies disease pathogenesis, with fructose metabolism playing a key role (6) .
The acute response to a fructose insult may provide valuable information on metabolic status of liver and kidneys. Recently, a metabolic challenge using fructose has been used to assay ATP availability in the liver (10) . The fructose challenge manifested changes in 31 P spectroscopy studies, with subjects that consumed a high level of dietary fructose reflecting lower ATP/inorganic phosphate ratio than subjects that consumed less. Fewer studies have investigated the impact of fructose on energy metabolism in the kidney (11) . Given the strong known association of diabetes and hypertension (exemplified in the metabolic syndrome), the impact could be significant; therefore, fructose metabolism in the kidney warrants further study as well.
Hyperpolarized (HP) 13 C MRI is a new method for investigating local tissue metabolism noninvasively, based 1 on >10,000-fold signal enhancement (12) compared with conventional 13 C NMR. HP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]pyruvate MRI was recently applied for first-in-man studies of cancer metabolism (13) . New preclinical studies have demonstrated the feasibility of probing gluconeogenic pathways using HP [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]dihydroxyacetone (DHAc) (14, 15) . DHAc has superior properties for imaging GNG/glycolysis compared with pyruvate, as it enters the Embden-Meyerhof pathway at dihydroxyacetone phosphate (DHAP) (Fig. 1) , sidestepping the rate limiting enzyme phosphoenolpyruvate carboxykinase (PEPCK). DHAc metabolism should be responsive to changes in the Embden-Meyerhof pathway induced by fructose. Furthermore, DHAc shares with pyruvate the favorable properties of long T 1 relaxation time (resulting in long signal lifetime) and rapid metabolism into multiple distinct metabolic pathways (providing rich metabolic data). Here, a spectrally selective imaging protocol (14) was used to image HP DHAc metabolism in the kidney and liver after an intravenous fructose challenge. The goal of this study was to investigate the effects of fructose vs. glucose challenge, as compared with controls, on metabolic status in the liver and kidneys using HP [2- 
METHODS

Hyperpolarization of [2-13 C]Dihydroxyacetone
A stock solution of [2-13 C]DHAc was prepared as in Marco-Rius et al 2016 (14) . Briefly, a sample containing 8 M [2-
13 C]DHAc (99% 13C, Sigma Aldrich, Miamisburg, OH), 21 mM trityl radical OX063 (Oxford Instruments, Abingdon, UK), and 1.0 mM gadolinium-DOTA chelate dissolved in 2:1 water:DMSO (vol/vol) was polarized using an Oxford HyperSense polarizer operating at 3.35 Tesla (T) and 1.3 K. The frozen sample was then dissolved in a superheated solution of phosphate-buffered saline to obtain a final concentration of 80 mM of [2- 13 C]DHAc with neutral pH.
Animal Preparation
All animal studies were carried out under a protocol approved by the University of California San Francisco (UCSF) Institutional Animal Care and Use Committee.
The concentration of glucose in the blood was measured immediately before the first DHAc injection and every 10-20 min after that using a glucometer (Contour, Bayer Corporation, Parsippany, NJ). A drop of blood was collected by pricking the end of the tail for every glucose reading. Glucose blood level measurements were corrected for the added blood volume due to injections in the rat, assuming an initial blood volume of 13.5 mL for every 0.25 kg of body weight (16) , which increased by 2.7 mL after each DHAc injection and by 0.7 mL after the fructose or glucose infusion.
Glucose and Fructose Loading Effects Probed with [2-13 C]Dihydroxyacetone
Thirteen Sprague Dawley rats (age ¼ 4-6 months, weight ¼ 0.4-0.5 kg) were fasted for 20-24 h with ad libitum water access, and anesthetized immediately before the MR spectroscopy (MRS) experiments by administration of inhalational isoflurane by means of nose cone (3.5% isoflurane/oxygen mixture for induction, gas flow rate 1 L/min). A tail-vein cannula was inserted, and its patency maintained with heparin diluted in sterile saline (4 U/mL). The animal was placed on a warm pad inside a dual-tuned birdcage coil to maintain its body temperature at 37 C and isoflurane delivery was kept at 1.5-1.7% (1 L/min) throughout the experiment. During each experimental session, all animals underwent multi-slice HP [2- 13 C]DHAc MRS scans at three time points (except one control that received only the first two): 0 (baseline), 70, and 140 min after baseline. Five animals received an intravenous bolus of 0.8 g/kg of fructose in phosphate buffer (0.5 g/mL, neutral pH) 60 min after the first DHAc injection (10 min before the second DHAc injection), 4/13 were given an intravenous bolus of 0.8 g/kg of glucose in phosphate buffer (0.5 g/mL, neutral pH) 60 min after the first DHAc injection (10 min before the second DHAc injection), and 4/13 were used as controls (did not receive any glucose or fructose but received three doses of DHAc). 13 C RF power and center frequency calibration were performed using a 1 mL vial filled with 6.0 M 13 C-urea placed on the rat abdomen in the coil.
Hyperpolarized [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]DHAc was injected into the tail vein of a rat over 12 s (2.7 mL, 80 mM solution, < 20 s after dissolution). Dynamic 13 C MRS acquisition started 15 s after the beginning of the injection.
Two adjacent axial slabs of 1 cm thickness centered on the liver and kidneys, respectively, were excited in a dynamic, alternating manner using a five-band spectralspatial RF pulse centered on a urea phantom resonance (d urea ¼ 163.2 ppm). The inter-slice spacing was 15-20 mm, depending on rat anatomy (Fig. 2 ). There was a temporal delay of 1.5 s between the liver and kidney acquisitions. Additional acquisition parameters included: TR for dynamic acquisition ¼ 3 s; receiver bandwidth ¼ 10 kHz; number of points ¼ 2048; flip angle ¼ 0. 3 at the DHAc resonance (d C2-DHAc ¼ 213 ppm), 26 at the phosphoenolpyr-
at the DHAc hydrate resonance (d C2-hydr ¼ 96 ppm), 20 at an additional resonance at 88 ppm, and 20 at the glycerol 3-phosphate (G3P) resonance (d C2-G3P ¼ 73 ppm).
Data Processing and T 1 Calculation
Data were processed using Matlab (Mathworks, Natick, MA). Before Fourier transformation, raw data were truncated to 1000 points, a 10 Hz line broadening was applied, and data were zero-filled to 4000 points. The spectral baseline offset was corrected by calculating the mean intensity of the noise (400 points on the edge of each spectrum) and subtracting it from all of the points in the spectrum.
The areas under the metabolic peaks of interest (magnitude spectra) were measured to obtain a time-course of the signal decay. Integral limits were defined for liver and kidney spectra separately. The same integral limits were used across the three spectra of the same organ acquired in the same experimental session. Figure 4 displays the results after summing the integral values of the first 10 acquisitions, normalized to the DHAc hydrate sum in the same slab. This ratiometric approach of normalizing to the hydrate was selected to minimize variations due to several factors, including substrate polarization, concentration, volume of infusion, tracer delivery, and coil loading and placement.
To calculate the apparent T 1 s of the metabolic products of DHAc in vivo, the integrals of the resonances of the metabolic products of HP DHAc were corrected for the applied flip angle and an exponential decay was fitted to the timecourse of the corrected integrals. A summary of the apparent T 1 results are presented in Table 1 .
Statistical Analysis
All results are expressed as mean 6 standard deviation. Statistical significance of the results was determined calculating a two-way, repeated-measurement analysis of variance (ANOVA) with Tukey's multiple comparison test in Prism 7 (GraphPad Inc., La Jolla, CA). Performing one ANOVA test for each metabolite and organ, the test accounted for the three groups and the repeated, matched measurements. One control rat that received only two DHAc injections was excluded from the statistical analysis. An adjusted P-value < 0.0167 (Bonferroni correction for three ANOVA tests) (17) was considered significant (0.001 < P < 0.0167 was indicated with *, and P < 0.001 was indicated with **).
RESULTS
Characterization of the MRS Spectra of Hyperpolarized [2-13 C]Dihydroxyacetone
To assign the resonances produced through the metabolism of [2- H image was acquired using a 3D bSSFP sequence. (Fig. 3) . Because the G3P doublet was much larger than the GA3P signal, they were integrated together, and throughout we will use G3P to refer to the area including both metabolites.
The lifetime of HP DHAc at 3T was sufficiently long to be used as a substrate to study metabolism (T 1 ¼ 39 s in solution, 20 s in vivo, estimated from a separate acquisition using a conventional slice-selective sinc RF pulse centered on the DHAc resonance). Table 1 shows the apparent T 1 relaxation times of G3P and DHAc hydrate in vivo, which were determined by fitting an exponential decay function to the time curve of the integrals of the resonances of the metabolic products of HP DHAc (corrected for the applied flip angle). The apparent T 1 s of G3P (30s) and DHAc hydrate (17s) were the same in the kidneys and in the liver. The signal intensity of PEP was too low to determine the T 1 accurately. Based on the disappearance of the PEP signal after 3-4 acquisitions (25 s after the beginning of the injection), the estimated apparent T 1 of PEP was 5-10 s in vivo. Because there were no differences among repeated HP DHAc injections, apparent T 1 data of the metabolites is presented as one value (n ¼ 39).
An example of the time-course of the integrals for liver and kidneys is shown in Figure 5 .
Assessment of the Metabolic Effects of
Hyperpolarized [2-
C]Dihydroxyacetone
To test whether the repeated injection of HP DHAc produced any metabolic changes, a control group (n ¼ 4) received three injections of HP DHAc alone, each 70 min apart (except one control rat that received only the first two injections).
Glucometer readings in Figure 4a (black circle) taken every 10-20 min indicate that repeated injections of 80 mM HP DHAc solution did not induce detectable changes in blood glucose levels (there was a 6 30 mg/dL intrinsic variability of the glucometer readings).
Also, in the control group no metabolic changes were detected by 13 C-MRS when probed with DHAc, i.e., the ratios G3P/DHAc hydrate and PEP/DHAc hydrate in liver (Fig. 4b) and kidneys (Fig. 4c) did not change significantly across the three injections.
Glucose Loading Effects on Metabolism Probed with [2-13 C]Dihydroxyacetone
Four Sprague Dawley rats received an intravenous bolus of glucose solution (0.8 g/kg) 60 min after the first HP DHAc injection (i.e., baseline), and their metabolism was probed with two additional HP DHAc injections at 70 and 140 min after baseline. The glucose concentration in blood increased immediately after glucose administration, surpassing 300 mg/dL 7 min after glucose infusion. A maximum of (328 6 45) mg/dL (n ¼ 4) was reached 20 min after glucose infusion, which is 3 times the baseline level (Fig. 4a, blue square) . Despite this increase in the blood glucose level, no metabolic changes were detected by probing the metabolism of liver and kidneys with DHAc, i.e., the integral of the G3P and PEP resonances remained at baseline levels. Eighty minutes after glucose infusion, blood glucose levels had dropped to just 30% higher than baseline, and the DHAc spectra showed no differences with the previous two 13 C-MRS acquisitions (Figs. 3b, 4b,c) .
Fructose Loading Effects on Metabolism Probed with [2-13 C]Dihydroxyacetone
A bolus of fructose given at the same dose as glucose, (0.8 g/kg), also produced an increase in the blood glucose level, albeit the maximum [(212 6 30) mg/dL, n ¼ 4] was only 1.8 times larger than the baseline blood glucose value (Fig. 4a, red triangle) . For the first 10 min postfructose infusion, the glucose concentration in blood remained close to baseline levels. The increase was noticeable approximately 20 min after the fructose injection, while the maximum level was reached 30-40 min after administration of fructose. Ten minutes after fructose infusion, blood glucose levels had not departed from baseline. However, the integral of the G3P and PEP metabolic peaks in the liver decreased with respect to baseline by 47% (P ¼ 0.0001) and 51% (P ¼ 0.0010), respectively (Figs. 3c, 4b ). In the kidneys, the slight decrease of the G3P integral measured was not significant (11%, P ¼ 0.0731) (Figs. 3c, 4c) .
Seventy minutes later (third HP DHAc injection), both blood glucose levels and resonances had returned to baseline. No statistical significance was found between baseline and 140 min later in any of the groups. The integrals of the G3P and PEP in the liver increased significantly with respect to the 10 min time point (second HP DHAc injection) by 150% (P ¼ 0.00002) and 109% (P ¼ 0.0039), respectively (Figs. 3c, 4b ; Supporting Figs. S2, S3). In the kidneys, there was a significant 28% increase of the G3P signal (P ¼ 0.0028).
DISCUSSION
Hyperpolarized [2-13 C]Dihydroxyacetone as a Metabolic Imaging Agent
Our results demonstrate the feasibility of using HP DHAc to assess gluconeogenic metabolism and ATP availability in the liver and in the kidneys noninvasively, which could potentially alter patient care standards, minimizing patient pain and discomfort associated with biopsies (particularly in patients with clotting problems due to liver dysfunction), and enabling longitudinal studies of disease progression or the effects of treatment (6) .
We have shown that HP DHAc satisfies key requirements for HP metabolic imaging, including high polarization (15%, providing a 50,000-fold increase in detection sensitivity at 3T), and sufficiently long T 1 of DHAc and its downstream metabolites to acquire kinetic data in vivo ( Fig. 5; Table 1 ). Moreover, the uptake and metabolism of DHAc is on the timescale of T 1 . DHAc enters the glycolytic/gluconeogenic pathway at the DHAP level (Fig. 1) , and it has previously been shown that in perfused liver it is 68 Marco-Rius et al.
rapidly metabolized into upstream and downstream metabolites (15) . Our results in vivo indicated that liver but not kidney is the primary site of DHAc metabolism.
Here, MRS signal localization is limited to 1-cm slabs.
The "liver slab" comprises mainly the liver, with traces of stomach, spleen and vasculature. The kidneys are the metabolically active organs enclosed in the "kidney slabs," but the circulating HP substrate in the aorta contributes to 13 C-MR spectra of three injections of HP DHAc, each separated by 70 min in time. b: As in (a), but with the additional bolus injection of a glucose solution (0.8 g/kg) 10 min before the acquisition of the second DHAc spectra. c: As in (a), but with the additional bolus injection of a fructose solution (0.8 g/kg) 10 min before the acquisition of the second DHAc spectra. The concentration of glucose in blood was monitored every 10-20 min (Fig. 4a) . DHAc ¼ dihydroxyacetone; G3P ¼ glycerol-3-phosphate; PEP ¼ phosphoenolpyruvate; hydr ¼ DHAc hydrate.
Monitoring Metabolic Changes with [2-
13 C]Dihydroxyacetonethe HP DHAc and hydrate signal. Because the kidney slab produces a larger HP DHAc hydrate signal than the liver, and perfusion and metabolic uptake is different in each organ, the acute changes in the metabolites ratios at the three time-points are compared for liver and kidneys independently.
While the precise mechanism of DHAc transport is not known, its entry into the hepatic Embden-Meyerhof pathway is rapid as evidenced by the downstream metabolites observed. DHAc kinase produces DHAP from DHAc, and has an activity of 0.71 units/mg protein in the rat liver (18) . Similar activities for the kinase are expected in the kidney (19) . Because the amplitudes of downstream DHAc metabolites in the kidney are notably decreased as compared to the liver (Fig. 3) , we surmise that transport of DHAc into kidney is restricted on the timescale of the MR experiment. Also, the higher hepatic metabolism of fructose is evidenced by the muted effect of the fructose challenge in the kidney as compared to the liver (20) (Figs. 4b,c) . The origin of the resonance at 89 ppm has not been identified. Because we did not detect this peak in solution, it is possible that it arose from metabolic conversion, but is currently unidentified.
The results indicate that DHAc produces minimal interference of the metabolic pathway of interest. Our study design included multiple injections of DHAc to assess the serial effects of the substrate administration on glucose homeostasis (21) . Figure 4a and Supporting Figure S1 demonstrate that the quantity of DHAc used for metabolic imaging does not perturb circulating glucose levels.
Glucose Challenge
Intravenous glucose was administered after a fast of 24 h, when the rat liver would be expected to be in a gluconeogenic regime with little stored glycogen remaining (22) . Circulating glucose is transported into liver cells by Glut2, where glucokinase phosphorylates glucose and prevents its export (2) . Despite ATP usage by this process, the glucose challenge failed to produce significant changes in any of the measured variables ( Fig. 4 ; Supporting Figs. S2, S3) . Because of the tight metabolic regulation associated with glucokinase, it is highly likely that hepatic glucose uptake was well controlled, and, therefore, glycolysis/GNG was largely unperturbed. Additionally, it has been reported that the glucose regulatory system of rats is less responsive to an increase in the circulating glucose than other animal species (23) . The lack of variability in the measured parameters using the Percentage change between the metabolites integrals at baseline and 10 min or 80 min after the carbohydrates infusion, which was administered 60 min after the baseline. c: Kidneys results: Percentage change between the metabolites integrals at baseline and 10 min or 80 min after the carbohydrates infusion. Error bars correspond to the standard deviation of the mean. Statistical significance was only observed in the fructose group and indicated with one asterisk, *(0.001 < P < 0.0167) or two, **(P < 0.001). DHAc ¼ dihydroxyacetone; G3P ¼ glycerol-3-phosphate; PEP ¼ phosphoenolpyruvate.
glucose challenge serves as an excellent control for the fructose challenge.
A recent study reports a large change on HP pyruvate metabolism by the kidney due to acute sucrose ingestion (24) . The oral glucose tolerance test has some important biological differences compared with the intravenous glucose challenge. An equivalent quantity of intragastric glucose, as in normal meal ingestion, is associated with a much larger insulin response, by means of the incretin effect (25), i.e., gut-specific glucose sensors that stimulate insulin secretion from the pancreatic beta-cells are by-passed when glucose is injected intravenously. Furthermore, ingested glucose is delivered to the liver first by means of the portal vein, while intravenously injected glucose is distributed in the systemic circulation, reaching heart, brain, lungs, and kidneys before being delivered to the liver (26) .
Fructose Challenge
The metabolism of fructose is well-known for its highly gluconeogenic nature (21) , but it is also connected to glycolysis, glycogen synthesis, and lipogenesis (20, 27) (Fig.  1) . A high-fructose diet, for example, induces long term changes in ATP availability and enzyme activities (10) . The rats used here were fed on normal chow; therefore, any metabolic changes detected with our method result solely from the acute effect of the bolus of fructose injected.
The infusion of fructose, which is also transported into the cells by Glut2, results in accumulation of fructose 1-phosphate (F1P) due to a high fructokinase activity, low aldolase B activity, and a shifted equilibrium constant toward F1P (28) . The conversion of fructose to F1P depletes the liver of ATP as the process is not strongly regulated, and the inorganic phosphate pool needed for phosphorylation of ADP is challenged (28, 29) . This perturbation of the energy homeostasis triggers several biochemical reactions, such as the inhibition of phosphorylase a and enhanced glycogen production (30) . The two trioses resulting from the metabolism of F1P (DHAP and glyceraldehyde) can be further metabolized to enter the gluconeogenic/glycolytic/glycogen synthesis pathway (by means of GA3P) or the lipid synthesis pathway (by means of G3P) (Fig. 1) .
The fructose challenge produced significant drops (even with Bonferroni correction) in the liver PEP and G3P resonances ( Fig. 4b ; Supporting Figs. S2a, S3a) before any changes in the circulating glucose concentration (Fig. 4a) while kidney PEP and G3P remained unperturbed ( Fig. 4c; Supporting Figs. S2b, S3b) . Seventy minutes later, the G3P and PEP integrals had returned to baseline levels. In the kidneys, G3P integral changed significantly between the second and third DHAc shots. However, the lack of a significant difference between time-points 1 and 3, and between time-points 1 and 2, corroborate that the difference between points 2 and 3 was not indicative of an important change in biology following injection of fructose. This agrees well with the fact that fructose is mainly metabolized in the liver (27) . A decrease of the observed hepatic PEP and G3P may be explained by the decrease in ATP availability immediately after the fructose injection, which inhibits the phosphorylation of DHAc.
Additionally, it had been previously reported that DHAP concentration in liver increases 10 min after fructose administration (in continuous infusion in perfused liver (29) and after a bolus injection by means of tail vein in rats in vivo) (28) . In the context of our HP experiments, this may translate into an increase of the unlabeled pool of DHAP and a consequent decrease in carbon-13 labeled G3P and PEP production from the exogenous HP 13 C-DHAc. These experiments at 3T, like prior experiments in perfused liver at 9.4T (15), were not able to distinguish the DHAP resonance from DHAc. Because the high HP DHAc signal would mask any changes in DHAP and no additional information would be extracted from this resonance, a spectral-spatial pulse was used to minimize excitation of DHAc (and DHAP) and preserve magnetization of the metabolites beyond DHAP.
While changes in individual metabolites were significant, the ratio of G3P/PEP was not particularly sensitive to any protocol used here. Although this is in apparent contradiction to previous work (15) , a closer analysis of fructose metabolism provides a possible explanation. While fructose is highly gluconeogenic, it does not drive GNG from 3-carbon metabolism and the TCA cycle. Given that it consumes phosphate moieties in its initial metabolism to F1P and drives 3-carbon intermediate pool sizes, changes in DHAc metabolism would most likely manifest in the 6-carbon intermediates of the Embden-Meyerhof pathway. Unfortunately, with the sensitivity achieved, these intermediates were not detected using the current protocol. Future experiments could be enhanced by using proton decoupling or higher field DNP polarizers that produce commensurate increases in the signal enhancement.
CONCLUSIONS
We have demonstrated that DHAc metabolism is responsive to fructose challenge. Because DHAc enters the glucose metabolism at the intermediate triose phosphate level, in the vicinity of fructose, it is ideally suited for assessing changes in aberrant glucose or glycerol metabolism. This observation is complementary to prior 31 P NMR studies in humans (10) . DHAc may probe alterations in hepatic energy homeostasis or key enzyme activities (such as G3P dehydrogenase) occurring in diabetes (31), NASH (32), obesity (10, 33, 34) or cirrhosis (35) , in a noninvasive manner. The clinical translational potential of this probe benefits from an exceptional safety profile, having been given as an oral metabolic challenge nearly a century ago (36) . Future work is proceeding along these lines.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article. Fig. S1 . Time-course of the glucose concentration in blood after repeated DHAc injections and either glucose or fructose infusion. The time of each DHAc injection is indicated with a numbered black circle. Glucometer readings (a) and corrected measurements (b) accounting for the increase in the total blood volume after each injection and infusion. Error bars correspond to the standard deviation of the mean. Fig. S2 . Box and whiskers plots of the metabolic response of the liver and kidneys in vivo after fructose or glucose loading. Liver (a) and kidneys (b) results: Metabolites integrals at three time points: 0 (baseline), 70 and 140 min. The carbohydrates were infused 60 min after the baseline. Statistical significance was only observed in the fructose group and is indicated with one asterisk, *(0.001 < P < 0.0167) or two, **(P < 0.001). DHAc 5 dihydroxyacetone, G3P 5 glycerol-3-phosphate, PEP 5 phosphoenolpyruvate, hydr 5 DHAc hydrate, Con 5 control group, Gluc 5 glucose group, Fruc 5 fructose group. Fig. S3 . Time-course of the mean 6 SD of the data displayed in supporting Figure S2 . Statistical significance was only observed in the fructose group and is indicated with one asterisk, *(0.001 < P < 0.0167) or two, **(P < 0.001). G3P 5 glycerol-3-phosphate, PEP 5 phosphoenolpyruvate, hydr 5 DHAc hydrate.
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